Fusen Pharmaceutical Company Limited (FUSEN PHARM, HKEX: 01652) announced that its wholly owned subsidiary, Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited, has obtained marketing approval from the National Medical Products Administration of the People’s Republic of China (NMPA) for “Peramivir Injection”, an antiviral treatment for influenza A and B.

Peramivir Injection is currently the only anti-influenza injectable therapy cleared by the U.S. Food and Drug Administration and is the first neuraminidase inhibitor approved in China for intravenous use. The drug is indicated for severe influenza cases and for patients unable to tolerate oral Oseltamivir, delivering rapid fever reduction and relief of symptoms such as nasal congestion, rhinorrhoea, expectoration, and cough. The product can be administered across all age groups.

Classified as a Class B medicine under China’s National Healthcare Security Administration, Peramivir Injection is endorsed by multiple domestic clinical guidelines, including the Chinese Guidelines for the Diagnosis and Treatment of Influenza and related expert consensuses for both adults and children. According to Menet data, combined sales of Peramivir-related drugs across three major terminals and six key markets in China surpassed RMB 800.00 million in 2025, underscoring robust market demand.

The addition of Peramivir Injection broadens FUSEN PHARM’s anti-infective portfolio and is expected to diversify treatment options for influenza A and B patients in China, complementing the Group’s existing product pipeline.